ESMO gastrointestinal oncology
TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomes
By Tong Y, Nakayama I, Sakamoto N and 18 others.
Abstract
Background
Trophoblast cell surface antigen 2 (TROP2) is frequently expressed in solid tumors, including gastric cancer (GC) and gastroesophageal junction cancer (GEJC), but its distribution and clinical relevance remain unclear. Patients and methods: We analyzed patients with GC/GEJC who underwent prospective multibiomarker testing. TROP2 expression was assessed by immunohistochemistry using multiple cut-offs and associations with clinicopathological features, biomarkers, and outcomes were evaluated.
